2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Balance in Spinocerebellar Ataxia (SCA): Comparison Between Type 10 and Type 3

H. Teive, K. Konno, M. Zonta, A. Guimarães (Curitiba, Brazil)
Barriers to exercise in newly diagnosed Parkinson’s disease

I. Argyropoulos, E. Pearson, F. Murphy, V. Queen, J. Rideout, C. Carrollq (Plymouth, United Kingdom)
Basal Ganglia and Limbic Striatal Regions are Differentially Affected by Pramipexole: D3 receptor – Mediated Changes in Markers of Synaptic Strength

M. Bailey, A. Persons, T.C. Napier (Chicago, IL, USA)
Basal Ganglia Circuits for Motor and Behavioral, Emotional Performances

F. Fujiyama (Kyotanabe, Japan)
Basal Ganglia Infarction and Striatal Toe- A Case Report

S. Usar Incirli, F. Selcuk Muhtaroglu, C. Akbostanci (Nicosia, Cyprus)
Baseline characteristics associated with greatest improvement in HRQL after DBS surgery

P. Schmidt, F. Cubillos, C. Martinez-Rubio, K. Lyons, C. Marras, T. Davis, E. Nelson, M. Okun (Miami, FL, USA)
Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD

W. Olanow, A. Ellenbogen, R. Djaldetti, T. Rachmilewitz Minei, Y. Cohen, S. Oren, K. Kieburtz (New York, NY, USA)
Baseline Clinical Predictors of Future Psychotic Symptoms in de novo Parkinson Disease

M. Barrett, M. Smolkin (Charlottesville, VA, USA)
Baseline multimodal information predicts future motor impairment in premanifest Huntington’s disease

E. Castro, P. Polosecki, I. Rish, G. Cecchi (Yorktown Heights, NY, USA)
Baseline predictors for clinical progression after 48 month follow-up in early Parkinson’s disease from the DeNoPa cohort

B. Mollenhauer, J. Zimmermann, F. Sixel-Döring, N. Focke, T. Wicke, J. Ebentheuer, M. Schaumburg, E. Lang, C. Trenkwalder (Kassel, Germany)
Baseline risk factors of insomnia symptoms after five years of follow-up: a population-based cohort of incident Parkinson’s disease

A. Duarte Folle, B. Ritz, K. Paul (Los Angeles, CA, USA)
Battery consumption and need for replacement in patients with Parkinson disease treated with interleaved deep brain stimulation

L. Deuel, J. Pilitsis, A. Ramirez-Zamora (Albany, NY, USA)
Behavioral and psychological symptoms in Parkinson’s disease with SWEDDs

J. Ahn, H. Kim (Seoul, Republic of Korea)
Behavioral Changes on the UCSD Huntington’s Disease Behavioral Questionnaire (HD-BQ) Distinguish Patients Transitioning to Manifest Huntington’s disease (HD)

S. Park, S. Nam, A. Nathan, A. Haque, A. Haque, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)
Beneficial and Protective Effects of Withania Someniferais On Mice Brain: A Therapeutic Potential Drug for Parkinson’s Disease

S. Rajput, S. Sinha (New Delhi, India)
Beta oscillatory changes during practice and retention of motor skills in healthy subjects and patients with PD

A. Nelson (NY, USA)
Beyond shuffling: Gait phenotypes in Parkinson’s Disease

L. Solis-Cohen, C. Ashton, D. Simon, M. Fox, D. Tarsy, R. Alterman, V. Vanderhorst, L. Shih (Boston, MA, USA)
Blink reflex recovery cycle in patients with genetically determined ataxias

S. Tunc, A. Weissbach, E. Werner, N. Baginski, J. Lubs, A. Münchau, T. Bäumer (Luebeck, Germany)
Blink reflex recovery cycle to differentiate Progressive Supranuclear Palsy from Corticobasal Degeneration

G. Sciacca, A. Nicoletti, G. Mostile, A. Luca, L. Raciti, V. Dibilio, F. Le Pira, M. Zappia (Catania, Italy)
Body mass index, change in body mass index and risk of Parkinson`s disease

J. Lee, J.H. Kim, J.H. Cho, G.S. Kim, J.H. Lee, P.H. Lee, Y.H. Sohn (Goyang-shi, Republic of Korea)
Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)
Brain insulin resistance in Parkinson’s disease

F. Bassil, M.-H. Canron, N. Dutheil, A. Vital, E. Bezard, P.-O. Fernagut, W. Meissner (Bordeaux, France)
Brain iron accumulation in Wilson disease measured by quantitative susceptibility mapping

P. Dusek, M. Dezortova, V. Herynek, J. Acosta-Cabronero, L. Kotackova, D. Zahorakova, S. Robinson, F. Jiru, R. Bruha, Z. Marecek, M. Hajek (Praha, Czech Republic)
Brain metabolic patterns in progressive supranuclear palsy phenotypes

M.M. Carmona-Abellan, A. Fontes, E. Prieto, J. Arbizu, R. Luquin, M. Riverol (Pamplona, Spain)
Brain PET metabolic substrate of Impulse Control Disorders in Parkinson’s Disease

E. Robin, A. Verger, F. Fluchere, T. Witjas, J.P. Azulay, E. Guedj, A. Eusebio (Marseille, France)
Brain structural and functional changes associated with frequent falls in Parkinson’s disease

H. Otomune, M. Mihara, H. Fujimoto, Y. Kajiyama, K. Konaka, Y. Mitani, G. Revankar, H. Mochizuki (Suita, Japan)
Brain volume changes in relation to intracortical inhibition and clinical benefit of pallidal stimulation in dystonia: a combined VBM and TMS study.

R. Jech, A. Fečíková, V. Čejka, V. Čapek, D. Šťastná, F. Růžička, D. Urgošík, E. Růžička (Prague, Czech Republic)
Brainstem connection of Writer’s cramp: Electrophysiological correlates

S. Choudhury, P. Chatterjee, R. Singh, S. Shubham, S. Trivedi, M. Baker, S. Baker, H. Kumar (Kolkata, India)
Brainstem reflexes in patients with neuroleptic-induced akathisia

A. Gunduz, B. Metin, S. Metin, B. Poyraz, M. Özmen, G. Kiziltan, M. E. Kiziltan, D. Karadeniz (Istanbul, Turkey)
Burden of autonomic neuropathy in Parkinson’s disease patients treated with advanced therapies

A. Romagnolo, A. Merola, M. Rosso, C. Comi, C. Artusi, M. Rizzone, M. Zibetti, S. Maule, L. Lopiano, A. Espay (Turin, Italy)

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z